Cancer cells are typically rapidly dividing, which allows the tumor to grow and become a threat to patient health.
Chemotherapy drugs that target DNA, such as the platinum-based class of alkylating agents, chemically modify the DNA such that cellular replication is inhibited. This process retards tumor growth and causes cell death. However, some tumors tolerate the drugs much better than others via a variety of complex mechanisms.
Platinum-based drugs cure some patients, while many others do not respond at all. The PlatinDx assay is being developed to predict tumor capacity to tolerate exposure to platinum drugs and predict efficacy of the therapy for individual patients.
PlatinDx is based upon the measurement of a drug-DNA adduct frequency ratio obtained in a microdosing setting—a nontoxic approach for quantifying cellular responses to chemotherapy in vivo. PlatinDX requires the patient be exposed intravenously to a sub-therapeutic dose, called a microdose, which is 1% of the therapeutic dose of a platinum-based anti-cancer agent. This dose is low enough so as to be safe for patients, but sufficient to allow measurement of drug-DNA damage formation in tumors.
With time, the drug enters the tumor cells and forms drug-DNA damage, which we can measure the with a proprietary mass spectrometry protocol. The resulting information can be used by physicians to decide whether subsequent full-dose chemotherapy is appropriate for that patient.
Accelerated Medical Diagnostics is currently conducting clinical studies aimed proving the PlatinDx concept in the clinic, obtaining regulatory approval and gaining reimbursement from payers.